Tag:
SGLT2 drugs
Latest Headlines
Latest Headlines
Rival giants team on diabetes as Merck partners with Pfizer on SGLT2 combo
Jockeying for a leading position in the high-stakes race to develop a new generation of blockbuster diabetes drugs, Merck is hitching a ride with Pfizer's late-stage SGLT2 candidate, ertugliflozin (PF-04971729).
UPDATED: J&J wins first FDA approval for new class of diabetes drug
The FDA has approved the first drug in a new class of blood glucose-lowering diabetes drugs: Johnson & Johnson's ( $JNJ ) Invokana ( canagliflozin ) for patients with Type II diabetes. The approval gives the healthcare giant its first market green light for a new diabetes therapy.
J&J's diabetes drug passes FDA panel test despite safety concerns
Johnson & Johnson emerged from a showdown with FDA advisers with some scratches but ultimately a win on Thursday. An agency advisory committee backed approval of the company's experimental diabetes drug canagliflozin in a 10-5 vote after reviewers highlighted concerns about increased heart risks in patients on the treatment.
Lilly, Boehringer ring up crucial PhIII successes for diabetes drug
Eli Lilly and its close diabetes drug development partner Boehringer Ingelheim laid out a slate of positive late-stage data for its SGLT-2 treatment empagliflozin this morning, taking a big step toward a new drug application expected later in the year.
Lexicon boasts of positive results in PhIIb diabetes study
Lexicon Pharmaceuticals says its SGLT1/SGLT2 inhibitor posted promising results in a Phase IIb study for treatment-resistant Type 2 diabetes.
UPDATED: ADA roundup: J&J's diabetes pioneer edges out Januvia in Phase III
Johnson & Johnson didn't disappoint close observers of the diabetes drug development field with its battery of late-stage results for the experimental diabetes drug canagliflozin.
J&J grabs ADA spotlight for new diabetes drug
Determined to build its stake in the fast-growing diabetes market, Johnson & Johnson plans to showcase late-stage data this weekend on its promising SGLT2 drug candidate that has drawn both praise and skepticism from clinicians and analysts.
